Evidence map›Paper›PMID 40599975›Full record

ArticleMolecular therapy. Nucleic acids2025

miR-107 represses

N Moreno, M Sabater-Arcis, J Espinosa-Espinosa, L Mulet-Rivero, E García-España, J González-García, D Seoane-Miraz, M J A Wood, M A Varela, J Ohana and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Local Non-Coding Regulatory Elements in Muscular Dystrophies.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

N MorenoHuman Translational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Av. Dr. Moliner 50, 46100 Valencia, Spain.
M Sabater-ArcisHuman Translational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Av. Dr. Moliner 50, 46100 Valencia, Spain.
J Espinosa-EspinosaExperimental and Applied Biomedicine Research Group, Health Sciences Faculty, Universidad Particular Internacional SEK, Alberto Einstein S/N, Quito 170120, Ecuador.
L Mulet-RiveroDepartment of Inorganic Chemistry, Instituto de Ciencia Molecular (ICMOL), University of Valencia, Catedrático José Beltrán Martínez, 2, 46980 Valencia, Spain.
E García-EspañaDepartment of Inorganic Chemistry, Instituto de Ciencia Molecular (ICMOL), University of Valencia, Catedrático José Beltrán Martínez, 2, 46980 Valencia, Spain.
J González-GarcíaDepartment of Inorganic Chemistry, Instituto de Ciencia Molecular (ICMOL), University of Valencia, Catedrático José Beltrán Martínez, 2, 46980 Valencia, Spain.
D Seoane-MirazDepartment of Paediatrics, Institute of Developmental and Regenerative Medicine (IDRM), University of Oxford, Roosevelt Dr. Headington, Oxford OX3 7TY, UK.
M J A WoodDepartment of Paediatrics, Institute of Developmental and Regenerative Medicine (IDRM), University of Oxford, Roosevelt Dr. Headington, Oxford OX3 7TY, UK.
M A VarelaDepartment of Paediatrics, Institute of Developmental and Regenerative Medicine (IDRM), University of Oxford, Roosevelt Dr. Headington, Oxford OX3 7TY, UK.
J OhanaSorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Batiment Babinski, GH Pitié-Salpétrière 47 bd de l'Hôpital, 75651 Paris Cedex, France.
T SevillaCIBERER ISCIII, Av. Monforte de Lemos 3-5, 28029 Madrid, Spain.
M Perez AlonsoHuman Translational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Av. Dr. Moliner 50, 46100 Valencia, Spain.
A BargielaCIBERER ISCIII, Av. Monforte de Lemos 3-5, 28029 Madrid, Spain.
R ArteroHuman Translational Genomics Group, University Institute for Biotechnology and Biomedicine (BIOTECMED), University of Valencia, Av. Dr. Moliner 50, 46100 Valencia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myotonic dystrophy type 1 (DM1) is a multisystem genetic disorder characterized by muscle disease, including muscle atrophy partially originating from excessive autophagy. We have previously demonstrated that excessive Musashi-2 (MSI2) repressed the biogenesis of miR-7, which derepressed autophagy, ultimately contributing to muscle atrophy, but the root cause of MSI2 dysregulation is unknown. Herein, we investigate the intricate role of miR-107 in DM1 pathogenesis, focusing on its involvement in the MSI2>miR-7>autophagy axis as this microRNA (miRNA) directly regulates MSI2. We found that in DM1, miR-107 function is impaired because expanded CUG repeats sequester it, causing an increase in the expression of its targets, including MSI2. Through different experimental approaches, including luciferase reporter assays, differential scanning fluorimetry, and electrophoretic mobility shift assay (EMSA), we confirm that miR-107 directly binds to CUG repeats in mutant

Indexed as

ASOCUG repeatsDM1DMPKmiR-107miRNAMSI2MT: Oligonucleotides: Therapies and Applicationsmuscle atrophy

Identifiers

PMID40599975
PMCPMC12212150

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.